leadf
logo-loader
viewBiocept Inc

Biocept appoints Dr Michael Dugan as chief medical officer and medical director

He will be responsible for medical policy decision-making and operations of the company’s high-complexity molecular laboratory in San Diego

Biocept Inc - Biocept appoints Dr Michael Dugan as chief medical officer and medical director
Dr Dugan has served in leading medical positions at Exact Sciences, Quest Diagnostics, Nichols Institute and Roche Molecular Systems

Biocept Inc (NASDAQ:BIOC), a leading commercial provider of liquid biopsy tests, announced Monday the appointment of Dr Michael Dugan as its chief medical officer and medical director. 

Dr Dugan has served in leading medical positions at Exact Sciences, Quest Diagnostics, and Roche Molecular Systems, Biocept noted. 

At Biocept he will be responsible for medical policy decision-making and the operations of the company’s CLIA-certified, CAP-accredited, high-complexity molecular laboratory in San Diego.

READ: Biocept expands availability of its COVID-19 testing services via large healthcare network

“Mike is highly respected in the molecular diagnostics industry, and we are thrilled to welcome him to our executive team,” said Biocept CEO Michael Nall in a statement. “Mike is particularly known within our industry for his outstanding leadership capability and commercial vision. He has proven experience in developing clinical strategies and designing and overseeing studies that validate clinical utility.”

Dr Dugan brings to Biocept more than 25 years of industry experience, most recently as president and CEO of MCDXI Medical Diagnostics International, a professional advisory group practice where he consulted with biotechnology companies in oncology diagnostics, medical device development, and clinically related software applications. 

Before that, he was senior medical advisor and chief medical officer at Clinical Genomics Inc, a biotechnology company developing an innovative product for colorectal cancer recurrence monitoring using circulating tumor DNA (ctDNA) in plasma. 

He has also been senior vice president of Clinical Development and Medical Affairs at Exact Sciences Corporation, medical director at Quest Diagnostics Nichols Institute (and Specialty Laboratories which they acquired), chief medical officer at bioTheranostics, vice president and chief medical officer at Roche Molecular Systems Inc, and vice president of Pathology Services at Genzyme Genetics (acquired by LabCorp).

“I’m excited to join Biocept to further develop and commercialize leading-edge assays that profile and monitor molecular signatures of cancer to help improve patient treatment choices and outcomes,” Dr Dugan said. 

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: Biocept Inc

Price: 4.36 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $58.4 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Biocept announces Highmark has made a positive coverage determination on...

Biocept (Nasdaq: BIOC) CEO Michael Nall joined Steve Darling from Proactive with news the company has received positive news from Highmark, America’s fourth-largest Blue Cross Shield affiliate. That news being Biocept's Target Selector liquid biopsy assays have been accepted for medical coverage...

on 23/9/20

2 min read